QT-019C UCAR T-cell therapy

QT-019C UCAR T-cell therapy · The Affiliated Hospital of Xuzhou Medical University

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for QT-019C UCAR T-cell therapy, covering 2026-02-11 to 2026-02-13. Get the full timeline:

Most recent: Clinical Trial Update: UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases [EARLY_Phase 1]

See pricing